VIRI News and Press, Virios Therapeutics Inc. From 11/14/22

Virios Therapeutics press release ( NASDAQ: VIRI ): Q3 GAAP EPS of -$0.28 beats by $0.21 . As of September 30, 2022, Virios Therapeutics’ cash totaled $9.8 million. The Company believes it will have sufficient resources to support the Long-COVID exploratory prog...

- FORTRESS Study Analysis Reveals Fibromyalgia Patients New to Research Demonstrate Significant IMC-1 Pain Reduction Treatment Benefits - - Company Believes FORTRESS Safety Data Supports Phase 3 Development, Requesting FDA Meeting to Discuss Next Steps - - Patient Dosi...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia , announced today that its third quarter 2022 financial results wil...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the closing of its previously announced underwritten publi...

Virios Therapeutics ( NASDAQ: VIRI ) shares dropped 24.5% after-hours on Monday as the firm has priced its underwritten public offering of 10.0M shares of its common stock at a public offering price of $0.50/share, for gross proceeds of $5.0M. All of the shares of comm...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the pricing of its underwritten public offering of 10.0 mi...

Virios Therapeutics ( NASDAQ: VIRI ) slid ~11% postmarket on Monday after the firm announced a proposed public stock offering . Net proceeds will be used primarily to advance clinical development of lead development candidate IMC-1, and for working capital and general...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that it intends to offer to sell shares of its common stoc...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock / PopTika Virios Therapeutics (NASDAQ: VIRI ) stock is falling hard on Monday after the company revealed results from its Phase 2b Study of IMC-1 in Fibromyalgia . IMC-1 is a treatment in...

Clinical-stage biotech Virios Therapeutics, Inc. ( NASDAQ: VIRI ) announced Monday that the company’s lead candidate, IMC-1, did not achieve statistical significance for the main goal in its Phase 2b trial involving patients with fibromyalgia. The FORTRESS study, desi...